Table 1. Comparison of visual acuity and mean CFT before and after ranibizumab treatment: baseline and outcome measures at 12mo.

Patients' studied eyes (n=121)	Baseline	Month 12	Change from baseline to month 12	P
Visual acuity letters (ETDRS letters)
x±s	43.2±19.3	51.7±20.1	8.5±0.97	<0.001
Median (IQR)	44 (34-60)	55 (35-66)	10 (0-15)	<0.001
CFT (µm)
x±s	526.5±277.0	258.2±161.6	-268.3±241.1	<0.001
Median (IQR)	440.0 (344.5, 628.5)	205.0 (164.5, 294.0)	-211.0 (-344.0, -115.0)	<0.001

CFT: Central foveal thickness; IQR: Interquartile range.